Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.


Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
28 02 2019
Historique:
received: 03 04 2018
revised: 03 01 2019
accepted: 04 01 2019
pubmed: 8 1 2019
medline: 23 5 2020
entrez: 8 1 2019
Statut: ppublish

Résumé

Acidic pH in the tumor microenvironment is associated with cancer metabolism and creates a physiological barrier that prevents from drugs to penetrate cells. Specifically, ionizable weak-base drugs, such as doxorubicin, freely permeate membranes in their uncharged form, however, in the acidic tumor microenvironment these drugs become charged and their cellular permeability is retarded. In this study, 100-nm liposomes loaded with sodium bicarbonate were used as adjuvants to elevate the tumor pH. Combined treatment of triple-negative breast cancer cells (4T1) with doxorubicin and sodium-bicarbonate enhanced drug uptake and increased its anti-cancer activity. In vivo, mice bearing orthotropic 4T1 breast cancer tumors were administered either liposomal or free bicarbonate intravenously. 3.7 ± 0.3% of the injected liposomal dose was detected in the tumor after twenty-four hours, compared to 0.17% ± 0.04% in the group injected free non-liposomal bicarbonate, a 21-fold increase. Analyzing nanoparticle biodistribution within the tumor tissue revealed that 93% of the PEGylated liposomes accumulated in the extracellular matrix, while 7% were detected intracellularly. Mice administered bicarbonate-loaded liposomes reached an intra-tumor pH value of 7.38 ± 0.04. Treating tumors with liposomal bicarbonate combined with a sub-therapeutic dose of doxorubicin achieved an improved therapeutic outcome, compared to mice treated with doxorubicin or bicarbonate alone. Interestingly, analysis of the tumor microenvironment demonstrated an increase in immune cell' population (T-cell, B-cell and macrophages) in tumors treated with liposomal bicarbonate. This study demonstrates that targeting metabolic adjuvants with nanoparticles to the tumor microenvironment can enhance anticancer drug activity and improve treatment.

Identifiants

pubmed: 30615983
pii: S0168-3659(19)30020-3
doi: 10.1016/j.jconrel.2019.01.004
pmc: PMC6660974
mid: EMS83803
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Liposomes 0
Doxorubicin 80168379AG
Sodium Bicarbonate 8MDF5V39QO

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-13

Subventions

Organisme : European Research Council
ID : 680242
Pays : International

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Nat Rev Cancer. 2017 Oct;17(10):577-593
pubmed: 28912578
Int J Nanomedicine. 2014 Sep 15;9:4357-73
pubmed: 25258527
Mol Ther. 2017 Jul 5;25(7):1467-1475
pubmed: 28412170
J Control Release. 2016 Dec 10;243:172-181
pubmed: 27744037
Mol Pharm. 2008 Jul-Aug;5(4):496-504
pubmed: 18611037
Br J Cancer. 2008 Aug 5;99(3):392-7
pubmed: 18648371
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2677-84
pubmed: 25687976
Cancer Cell Int. 2013 Sep 03;13(1):89
pubmed: 24004445
J Control Release. 2011 Apr 30;151(2):183-92
pubmed: 21262289
Int J Cancer. 1993 Apr 22;54(1):166-72
pubmed: 8478143
Clin Cancer Res. 2001 Feb;7(2):243-54
pubmed: 11234875
ACS Nano. 2013 Jan 22;7(1):438-46
pubmed: 23240550
Nanoscale. 2016 Jul 7;8(25):12639-47
pubmed: 26745389
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Cancer Res. 2009 Mar 15;69(6):2677-84
pubmed: 19276380
Eur J Pharm Biopharm. 2018 Aug;129:184-190
pubmed: 29859281
J Control Release. 2016 Feb 28;224:158-164
pubmed: 26774223
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Mol Pharm. 2011 Dec 5;8(6):2032-8
pubmed: 21981633
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
Mol Imaging Biol. 2014 Feb;16(1):53-62
pubmed: 23877869
Jpn J Cancer Res. 1998 Mar;89(3):307-14
pubmed: 9600125
Biochem Pharmacol. 2003 Oct 1;66(7):1207-18
pubmed: 14505800
Angew Chem Int Ed Engl. 2011 Feb 7;50(6):1242-58
pubmed: 21290491
Anal Biochem. 2005 Dec 1;347(1):34-41
pubmed: 16289011
Nanomedicine (Lond). 2015 May;10(10):1599-608
pubmed: 25694061
Biomaterials. 2012 Mar;33(7):2223-9
pubmed: 22182751
Biochim Biophys Acta. 1995 Feb 15;1233(2):134-44
pubmed: 7865538
Cancer Res. 2009 Mar 15;69(6):2260-8
pubmed: 19276390
Cancer Res. 2011 Nov 15;71(22):6921-5
pubmed: 22084445
Hear Res. 2003 Mar;177(1-2):21-31
pubmed: 12618314
Mol Pharm. 2011 Dec 5;8(6):2101-41
pubmed: 21974749
Nat Nanotechnol. 2012 Apr 08;7(6):383-8
pubmed: 22484912
Biochim Biophys Acta. 1993 Sep 19;1151(2):201-15
pubmed: 8373796
J Leukoc Biol. 2001 Apr;69(4):522-30
pubmed: 11310837
Cancer Chemother Pharmacol. 1994;34(3):197-202
pubmed: 8004751
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Nanomedicine. 2015 Oct;11(7):1841-50
pubmed: 26115641
Nat Nanotechnol. 2012 Aug;7(8):483-4
pubmed: 22864165
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Neurosci Lett. 2013 Jun 7;544:41-6
pubmed: 23570729
Mol Cancer Ther. 2006 May;5(5):1275-9
pubmed: 16731760
Angew Chem Int Ed Engl. 2012 Oct 1;51(40):10089-93
pubmed: 22952023
Int J Nanomedicine. 2013;8:61-71
pubmed: 23293520
Part Part Syst Charact. 2014 Dec;31(12):1307-1312
pubmed: 26380538
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
Invest New Drugs. 2002 Feb;20(1):101-4
pubmed: 12003184
J Drug Target. 2013 Dec;21(10):904-13
pubmed: 24079419
Nat Biotechnol. 2005 Nov;23(11):1418-23
pubmed: 16244656
Nat Commun. 2016 Nov 10;7:13325
pubmed: 27830705
Nat Rev Drug Discov. 2014 Nov;13(11):813-27
pubmed: 25287120
BMC Cancer. 2015 Jul 22;15:534
pubmed: 26198000
Nano Lett. 2017 Aug 9;17(8):4665-4674
pubmed: 28715227
Int J Cancer. 2001 Sep;93(6):869-74
pubmed: 11519050
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Oncoimmunology. 2013 Jan 1;2(1):e22058
pubmed: 23483769
Nanomedicine. 2013 Jan;9(1):1-14
pubmed: 22684017
Br J Cancer. 1999 Jun;80(7):1005-11
pubmed: 10362108
Biomaterials. 2010 Oct;31(30):7797-804
pubmed: 20673684
Br J Cancer. 1998 Mar;77(6):873-9
pubmed: 9528827
Int J Nanomedicine. 2015 Feb 11;10:1245-57
pubmed: 25709446
J Control Release. 2014 May 28;182:83-9
pubmed: 24631862
Cancer. 1986 Sep 15;58(6):1199-203
pubmed: 3091241
Theranostics. 2015 Sep 12;5(11):1291-302
pubmed: 26379793
Cancer Res. 1992 Feb 15;52(4):891-6
pubmed: 1737351
Oncogene. 2014 Jul 17;33(29):3812-9
pubmed: 23995783
ACS Nano. 2018 Feb 27;12(2):1482-1490
pubmed: 29365250
Cancer Res. 1992 Dec 15;52(24):6774-81
pubmed: 1458465
Adv Drug Deliv Rev. 2011 Mar 18;63(3):129-30
pubmed: 20457195
J Control Release. 2009 Jul 1;137(1):63-8
pubmed: 19303426
Nanotechnology. 2017 Oct 27;28(43):43LT01
pubmed: 28872058
Transl Cancer Res. 2013 Aug 1;2(4):309-319
pubmed: 24634853
Br J Cancer. 2012 Feb 28;106(5):916-22
pubmed: 22333602
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):398-400
pubmed: 11209044
Expert Opin Drug Deliv. 2015 Aug;12(8):1203-7
pubmed: 26083469
Int J Nanomedicine. 2017 Mar 06;12:1803-1813
pubmed: 28293107
Int J Nanomedicine. 2012;7:1251-8
pubmed: 22419872
Nat Nanotechnol. 2018 Sep;13(9):777-785
pubmed: 30190620
Cancer Res. 2015 Sep 15;75(18):3738-46
pubmed: 26216548
Curr Pharm Des. 2010;16(29):3255-63
pubmed: 20819068
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9
pubmed: 16203786
Int J Nanomedicine. 2014 Feb 19;9:1005-23
pubmed: 24600222
Semin Cancer Biol. 2017 Apr;43:74-89
pubmed: 28267587
Nat Rev Mater. 2016 Sep;1(9):
pubmed: 27668091
Int J Cancer. 2002 Jan 1;97(1):115-20
pubmed: 11774252

Auteurs

Hanan Abumanhal-Masarweh (H)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel; Russell Berrie Nanotechnology Institute, The Norman Seiden Multidisciplinary Graduate Program, Technion - Israel Institute of Technology, Haifa 3200, Israel.

Lilach Koren (L)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Assaf Zinger (A)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Zvi Yaari (Z)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Nitzan Krinsky (N)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel; The Interdisciplinary Program for Biotechnology, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Galoz Kaneti (G)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Nitsan Dahan (N)

Life Sciences and Engineering Infrastructure Center, Lorry I. Lokey Interdisciplinary Center, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Yael Lupu-Haber (Y)

Life Sciences and Engineering Infrastructure Center, Lorry I. Lokey Interdisciplinary Center, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Edith Suss-Toby (E)

Bioimging Center, Biomedical Core Facility, Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Esther Weiss-Messer (E)

Bioimging Center, Biomedical Core Facility, Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Michal Schlesinger-Laufer (M)

The Pre-Clinical Research Authority Unit, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Janna Shainsky-Roitman (J)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.

Avi Schroeder (A)

Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel. Electronic address: avids@technion.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH